NEW YORK, Jan. 12, 2015 /PRNewswire/ - Analyst report issued by Small Cap IR. Provectus Biopharmaceuticals, Inc. (NYSE: PVCT) is a biopharmaceutical company that primarily engaged in developing oncology and dermatology therapies through its two predominant drug candidates, PV-10 and PH-10. The company is working to develop PV-10 for the treatment of several life-threatening cancers, including metastatic melanoma, liver cancer (also known as Hepatocellular carcinoma, or HCC), and breast cancer. Its other drug candidate, PH-10, is being developed to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis (a type of eczema).
By completing Phase 2 trial, PV-10 showed a 51% objective response rate among all 80 intent-to-treat melanoma patients of their injected study tumors. Data released, showed that if a tumor is accessible to PV-10 injection, the drug is likely to destroy that tumor. In comparison to the other available options, PV-10 will provide a much better treatment plan with significant adverse side effects. Considering annual growth rate of 17% in the melanoma therapeutics market by 2017, PV-10 should open a new front line against cancer.
An analyst brief which covers a brief technical analysis, analyst recommendation and price target can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:
Copy and paste to browser may be required.
About Small Cap IR
An issuer of reports written by chartered financial analysts (CFA's) who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
For more information and services provided beyond this release please use contact information provided below.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Source: Small Cap IR
Contact: [email protected]
SOURCE Small Cap IR